HilleVax, Inc. (HLVX)
NASDAQ
Market Cap
$102.35M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
267 of 966
Rank in Industry
161 of 554
Largest Insider Buys in Sector
HLVX Stock Price History Chart
HLVX Stock Performance
About HilleVax, Inc.
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Insider Activity of HilleVax, Inc.
Over the last 12 months, insiders at HilleVax, Inc. have bought $149,550 and sold $2.11M worth of HilleVax, Inc. stock.
On average, over the past 5 years, insiders at HilleVax, Inc. have bought $15.07M and sold $493.96M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Frazier Life Sciences X, L.P. (10 percent owner) — $128,325. McLoughlin Sean (Chief Operating Officer) — $21,225.
The last purchase of 8,850 shares for transaction amount of $128,325 was made by Frazier Life Sciences X, L.P. (10 percent owner) on 2024‑04‑04.
List of Insider Buy and Sell Transactions, HilleVax, Inc.
| 2024-05-22 | Sale | director | 6,000 0.0126% | $14.73 | $88,372 | -86.78% | ||
| 2024-05-21 | Sale | director | 6,000 0.0118% | $14.21 | $85,230 | -87.08% | ||
| 2024-05-20 | Sale | director | 6,000 0.0129% | $15.45 | $92,689 | -87.09% | ||
| 2024-05-03 | Sale | director | 723 0.0015% | $14.15 | $10,233 | -86.11% | ||
| 2024-05-02 | Sale | director | 6,000 0.0121% | $14.01 | $84,081 | -86.48% | ||
| 2024-05-01 | Sale | director | 175 0.0004% | $14.03 | $2,456 | -86.00% | ||
| 2024-04-05 | Sale | director | 6,000 0.012% | $14.44 | $86,640 | -86.78% | ||
| 2024-04-04 | Sale | director | 6,000 0.0122% | $14.71 | $88,245 | -86.72% | ||
| 2024-04-04 | 10 percent owner | 8,850 0.0178% | $14.50 | $128,325 | -86.72% | |||
| 2024-04-03 | Sale | director | 6,000 0.0122% | $14.93 | $89,582 | -86.98% | ||
| 2024-03-28 | Chief Operating Officer | 1,250 0.0026% | $16.98 | $21,225 | -88.36% | |||
| 2024-03-20 | Sale | director | 6,000 – | $164,221.00 | $985.33M | -87.90% | ||
| 2024-03-19 | Sale | director | 6,000 0.0126% | $17.42 | $104,492 | -88.75% | ||
| 2024-03-18 | Sale | director | 6,000 0.0129% | $17.66 | $105,937 | -88.70% | ||
| 2024-03-08 | Sale | director | 6,000 0.0128% | $18.66 | $111,959 | -89.28% | ||
| 2024-03-07 | Sale | director | 6,000 0.0124% | $18.37 | $110,213 | -89.38% | ||
| 2024-03-06 | Sale | director | 6,000 0.0128% | $18.95 | $113,701 | -89.48% | ||
| 2024-02-22 | Sale | director | 6,000 0.0127% | $15.05 | $90,312 | -19.53% | ||
| 2024-02-21 | Sale | director | 6,000 0.0126% | $14.92 | $89,495 | -19.15% | ||
| 2024-02-20 | Sale | director | 6,000 0.0127% | $14.88 | $89,272 | -18.92% |
Insider Historical Profitability
<0.0001%
| Frazier Life Sciences X, L.P. | 10 percent owner | 8544187 17.1549% | $2.06 | 1 | 0 | |
| HERSHBERG ROBERT | See Remarks | 953831 1.9151% | $2.06 | 0 | 1 | |
| Kohli Aditya | director | 764878 1.5357% | $2.06 | 0 | 19 | |
| Borkowski Astrid | Chief Medical Officer | 161260 0.3238% | $2.06 | 0 | 6 | |
| Maltbie Shane | Chief Financial Officer | 40656 0.0816% | $2.06 | 0 | 1 | |
| McLoughlin Sean | Chief Operating Officer | 1250 0.0025% | $2.06 | 1 | 0 | |
| Heron Patrick J | 8535337 17.1371% | $2.06 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Frazier Life Sciences Management L P | $162.67M | 19.67 | 9.78M | 0% | +$0 | 7.35 | |
| Deerfield Management | $66.59M | 8.05 | 4M | 0% | +$0 | 0.16 | |
| T Rowe Price Investment Management Inc | $50.92M | 6.16 | 3.06M | +110.6% | +$26.74M | 0.03 | |
| Deep Track Capital Lp | $42.78M | 5.17 | 2.57M | -11.29% | -$5.45M | 0.2 | |
| Vr Adviser Llc | $34.51M | 4.17 | 2.08M | 0% | +$0 | 1.68 | |
| Franklin Templeton Investments | $30.84M | 3.73 | 1.85M | +0.43% | +$133,040.00 | 0.01 | |
| The Carlyle Group | $30.5M | 3.7 | 1.84M | 0% | +$0 | 1.31 | |
| BlackRock | $29.94M | 3.62 | 1.8M | +1.37% | +$404,774.19 | <0.01 | |
| The Vanguard Group | $22.66M | 2.74 | 1.36M | -6.97% | -$1.7M | <0.0001 | |
| StepStone Group | $13.75M | 1.66 | 826,569 | 0% | +$0 | 2.93 | |
| Samsara Biocapital Llc | $13.29M | 1.61 | 799,274 | 0% | +$0 | 2.07 | |
| Millennium Management LLC | $11.25M | 1.36 | 676,566 | New | +$11.25M | 0.01 | |
| Citadel Advisors LLC | $10.8M | 1.31 | 649,376 | -10.35% | -$1.25M | 0.01 | |
| Geode Capital Management | $10.34M | 1.25 | 621,817 | +5.19% | +$510,156.76 | <0.01 | |
| Qiming U S Ventures Management Llc | $9.29M | 1.12 | 558,923 | 0% | +$0 | 10.36 | |
| State Street | $8.13M | 0.98 | 488,734 | +17.13% | +$1.19M | <0.0001 | |
| Deutsche Bank | $5.14M | 0.62 | 309,304 | +180.37% | +$3.31M | <0.01 | |
| ACUTA CAPITAL PARTNERS LLC | $4.17M | 0.5 | 250,609 | -22.8% | -$1.23M | 2.71 | |
| Northern Trust | $4.06M | 0.49 | 243,948 | -1.5% | -$61,946.76 | <0.01 | |
| Charles Schwab | $3.43M | 0.42 | 206,266 | -1.2% | -$41,691.42 | <0.01 | |
| Walleye Capital | $2.36M | 0.29 | 142,182 | -30.53% | -$1.04M | 0.01 | |
| Alger | $2.06M | 0.25 | 124,122 | -5.57% | -$121,814.76 | 0.01 | |
| Ensign Peak Advisors Inc | $1.96M | 0.24 | 117,746 | 0% | +$0 | <0.01 | |
| Dimensional Fund Advisors | $1.93M | 0.23 | 115,912 | +79.53% | +$853,900.81 | <0.0001 | |
| 683 Capital Management Llc | $1.88M | 0.23 | 113,000 | -6.77% | -$136,366.00 | 0.2 | |
| Bridger Management Llc | $1.8M | 0.22 | 108,200 | New | +$1.8M | 0.81 | |
| Adage Capital Partners Gp L L C | $1.23M | 0.15 | 74,220 | -62.6% | -$2.07M | <0.01 | |
| Barclays | $1.2M | 0.15 | 72,270 | +81.09% | +$538,247.18 | <0.01 | |
| BNY Mellon | $1.16M | 0.14 | 69,455 | -5.68% | -$69,529.99 | <0.0001 | |
| Morgan Stanley | $1.05M | 0.13 | 63,033 | -86.15% | -$6.52M | <0.0001 | |
| Wellington Management Company | $1.03M | 0.13 | 61,923 | New | +$1.03M | <0.0001 | |
| Nuveen | $805,058.00 | 0.1 | 48,410 | 0% | +$0 | <0.0001 | |
| JPMorgan Chase | $782,808.00 | 0.1 | 47,072 | +171.43% | +$494,410.30 | <0.0001 | |
| Ubs Oconnor Llc | $759,592.00 | 0.09 | 45,676 | -25.19% | -$255,819.33 | 0.04 | |
| Swiss National Bank | $635,266.00 | 0.08 | 38,200 | 0% | +$0 | <0.0001 | |
| Two Sigma | $625,654.00 | 0.08 | 37,622 | +25.13% | +$125,639.68 | <0.01 | |
| Td Asset Management Inc | $585,975.00 | 0.07 | 35,236 | +90.18% | +$277,854.19 | <0.01 | |
| RhumbLine Advisers | $558,508.00 | 0.07 | 33,585 | +5.84% | +$30,798.18 | <0.01 | |
| Jane Street Capital | $525,774.00 | 0.06 | 31,616 | +130.98% | +$298,142.59 | <0.01 | |
| Martingale Asset Management L P | $482,803.00 | 0.06 | 29,032 | +0.11% | +$532.16 | 0.01 | |
| UBS | $479,958.00 | 0.06 | 28,861 | -9.55% | -$50,704.82 | <0.0001 | |
| D. E. Shaw & Co. | $468,284.00 | 0.06 | 28,159 | New | +$468,284.00 | <0.0001 | |
| Bank of America | $465,806.00 | 0.06 | 28,010 | -39.37% | -$302,516.14 | <0.0001 | |
| State of Wisconsin Investment Board | $454,465.00 | 0.06 | 27,328 | +105.24% | +$233,036.38 | <0.01 | |
| Standard Life | $449,010.00 | 0.05 | 27,000 | 0% | +$0 | <0.01 | |
| Renaissance Technologies | $429,000.00 | 0.05 | 25,800 | New | +$429,000.00 | <0.01 | |
| New York Life Investment Management Llc | $374,375.00 | 0.05 | 22,512 | New | +$374,375.00 | <0.01 | |
| Stifel | $346,687.00 | 0.04 | 20,847 | New | +$346,687.00 | <0.0001 | |
| CalSTRS | $333,132.00 | 0.04 | 20,032 | -7.01% | -$25,111.29 | <0.0001 | |
| Woodline Partners LP | $315,804.00 | 0.04 | 18,990 | New | +$315,804.00 | <0.01 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.